ABSTRACT
and Cochrane Library databases. Eligible RCTs compared PTA with (S)ET, included patients with IC due to suspected or known aorto-iliac and/or femoro-popliteal artery disease, and compared their effectiveness in terms of functional outcome and/or quality of life (Qol).
Results
Eleven of 258 articles identified (reporting data on eight randomized clinical trials) met the inclusion criteria. One trial included patients with isolated aorto-iliac artery obstruction, three trials studied those with femoro-popliteal artery obstruction and five included those with combined lesions. Two trials compared PTA with advice on ET, four PTA with SET, two PTA plus SET with SET and two PTA plus SET with PTA. Although the endpoints in most trials comprised walking distances and Qol, pooling of data was impossible owing to heterogeneity. Generally, the effectiveness of PTA and (S)ET was equivalent, although PTA plus (S)ET improved walking distance and some domains of Qol scales compared with (S)ET or PTA alone.
Conclusion
As IC is a common healthcare problem, defining the optimal treatment strategy is important.
A combination of PTA and exercise (SET or ET advice) may be superior to exercise or PTA alone, but this needs to be confirmed. CHAPTER 
· SYSTEMATIC REVIEW OF ET OR PTA FOR INTERMITTENT CLAUDICATION

INTRODUCTION
Ability to walk is impaired in patients with intermittent claudication (IC) due to peripheral arterial disease (PAD). 1 One of the aims of care for patients with IC is to increase walking distance, and subsequently improve quality of life (Qol). 2, 3 Drugs, exercise therapy (ET), percutaneous transluminal angioplasty (PTA) or surgery can relieve symptoms. [4] [5] [6] [7] Exercise programmes and PTA are widely accepted therapies for IC. 7, 8 Two systematic reviews demonstrated the superiority of supervised exercise therapy (SET) over standard care or unsupervised ET in increasing both pain-free and maximum walking distance (MWD). 9, 10 PTA is attractive as an initial therapy as it is instantly effective and durable, especially in patients with iliac artery disease. 7, 11 A Cochrane review 12 summarizing the results of two randomized clinical trials (RCTs) [13] [14] [15] [16] found more short term benefit from PTA than conservative management (medication or ET), but this was not sustained after 1-2 years. Another review found that medical treatment (a home or supervised exercise programme, as well as risk factor modification) resulted in a longer walking distance than PTA at 1-2 years. 17 Thus, the optimal treatment for symptom relief, PTA, ET or both, is still unknown. Given that six additional RCTs have compared PTA and exercise in the past 5 years [18] [19] [20] [21] [22] [23] [24] [25] , an update on this topic is required in order to provide recommendations. The aim of this systematic review was to summarize the results of all RCTs comparing PTA with (S)ET to obtain the best estimates of their relative effectiveness.
METHODS
This review was done according to the Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) statement, which has been updated to address several conceptual and practical advances for performing a systematic review of RCTs.
26,27
Literature search
A clinical librarian provided assistance with a computerassisted search of the MEDLINE, Embase and Cochrane databases to identify RCTs on (S)ET versus PTA for IC published between January 1966 and September 2010. Medical Subject Headings (MeSH) terms were used, and accompanying entry terms for the patient group, interventions and outcomes.
The keywords 'angioplasty', 'intermittent Claudication', 'exercise therapy' were used, along with their synonyms (Table 1) . There was no language restriction. Reference lists of all eligible articles were checked for other relevant studies. Conference proceedings were not searched, and experts in the field were not contacted. 
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Study selection
Titles and abstracts were screened by two reviewers independently to identify potentially relevant articles. Discrepancies in judgement were resolved after discussion and, when necessary, after mediation by a third reviewer. Agreement between both observers for study selection was good (κ = 0.64). The full text of all potentially relevant articles was retrieved for further analysis. Studies were included if they met the following criteria: the patients had IC due to PAD and were allocated randomly to S(ET) or PTA with or without stent insertion.
The arterial lesions could be localized in the aorto-iliac and/or the femoro-popliteal tract.
Studies on PTA for treatment of critical limb ischaemia were excluded. If the same cluster of investigators reported their results in various journals, the papers were scanned for similarity and completeness, and the results combined in the review.
Quality assessment
The methodological quality of the included studies was assessed using the Cochrane checklist. 28 The following items were assessed: randomization; allocation concealment; blinding of patients, clinicians and assessors to the received treatment; similarity in baseline characteristics; completeness of follow-up of a sufficient number of included patients;
intention-to-treat analysis; and similarity of other treatment, aside from the allocated treatment.
Data extraction
Recorded study characteristics included: inclusion and exclusion criteria, total number of patients included and excluded, age, sex distribution, single-centre or multicentre design, intervention type, duration of follow-up, time of randomization, description of PTA technique and complications, secondary prevention, description of the treadmill test (speed, incline and duration), description of the exercise programme (frequency, duration, content)
and Qol questionnaires used. Recorded outcome measures included:MWD in metres (total walking distance until intolerable claudication pain forced the patient to stop), initial claudication distance (ICD) in metres (walking distance until onset of claudication pain), ankle : brachial pressure index (ABPI) at rest and Qol scores.
Data analysis
As it was anticipated that the interventions for (S)ET would be heterogeneous, a metaanalysis was planned in which the data would be pooled according to a random effects model, as long as clinical heterogeneity between studies was limited. 29 Pooled estimates of 
RESULTS
Some 257 articles were identified from the databases and one unpublished trial from a thesis, giving a total of 258 papers ( Fig. 1 ). Twenty-four papers were eligible after reading the title and abstract, and were retrieved as a full text for further analysis. Finally, 12 articles reporting data on eight RCTs fulfilled the inclusion criteria. One paper 14 was excluded because it reported 6-year follow-up of a trial that was already included, with 6-and 12-month results reported in another paper 13. Another reason for exclusion of this paper was incomplete follow-up for a substantial number of patients. The remaining 11 studies were used for data extraction and analysis. 13, 15, 16, [18] [19] [20] [21] [22] [23] [24] [25] 
Study and baseline characteristics
Results of the methodological assessment of the eight RCTs are presented in Table 2 .
The overall methodological study quality was mediocre, and there was only one trial of high quality. 22, 23 Four trials were terminated prematurely 13, 15, 16, [18] [19] [20] , and five were probably underpowered, or at least conducted without a power calculation.
13,15,16,18-21 Table 3 shows the inclusion and exclusion criteria for each trial, demonstrating the heterogeneity of study populations. Table 4 lists the number of patients screened and finally included in each trial, baseline characteristics, allocation of treatment, and the timing and nature of outcome assessments. Several trials included only a small proportion of the screened patients (range 6.2-51.4 per cent). A total of 702 patients were included in the eight trials. The mean age of these patients was 65.3 (range 61.6-69.5) years and the majority were men (62.5 per cent).
Interventions
Two trials compared PTA plus ET advice with ET advice alone 15, 16, 19, 20 , four compared PTA with SET 13, 18, [22] [23] [24] , two compared PTA plus SET with SET 21, 24 and two compared PTA plus SET with PTA24,25 ( Table 4) . Table 5 summarizes the diverse exercise programmes varying from homebased exercise without supervision 15, 16, 19, 20 to SET programmes
The exercise programme included dynamic leg exercises13, exercise advice 15, 16, 19, 20 , a walking circuit 21 , an exercise circuit 18, 24 and treadmill training 22,23,25. In four trials, the intervention covered both PTA with, or without selective stent placement [19] [20] [21] [22] [23] 25 ; the other trials referred to PTA alone.
Complications
Two trials did not report complications of PTA 18, 24 , and one did not report complications at all 15, 16 . One trial reported 'few' complications 19, 20 and the other four trials three, four, six and seven complications respectively 13, [21] [22] [23] 25 . These complications consisted primarily of haematomas, but bleeding, artery dissections and artery rupture also occurred. For (S)ET either no complications were reported, or no complications occurred. Compliance with (S)ET was mentioned occasionally, and reported as a percentage 21 , frequency per week 13 or mean total sessions attended 25 . Treatment failure, loss to follow-up or crossover to another intervention had multiple causes.
Secondary prevention (co-interventions)
Effective secondary prevention for cardiovascular events was outlined in recent guidelines. 6, 30 Secondary prevention with an antiplatelet drug and a statin can reduce the risk of cardiovascular events in this specific high-risk population. 31 Secondary prevention as given in the included RCTs reflected changing insights over a long time, and varied widely. In one RCT, patients allocated to PTA and already on an antiplatelet drug could continue their medication, but it was unclear whether the other patients were prescribed an antiplatelet drug. 13 Two RCTs prescribed an antiplatelet drug alone 15, 16, 21 , and one trial acted in accordance with the management of PAD in primary care, which was not specified 18 . One RCT advised an antiplatelet drug and a statin 24 , one recommended an antiplatelet drug, a statin and treatment of hypertension on indication 19, 20 , and another advised an antiplatelet drug, a statin and regular check-up by an internist of risk profile, diabetes, lipids and hypertension 22, 23 . The same holds for the remaining RCT, which also included lifestyle advice given according to the Dutch guidelines for cardiovascular risk management, and advice on smoking cessation 25 . As statins have been shown to increase walking distance in randomized trials 32, 33 , an attempt was made to determine the effect of statins on walking distance in the individual studies. Unfortunately, none of the papers described in detail how many patients were taking a statin (Table 4) . Assessment of outcome Table 6 shows the diversity in speed and duration for the treadmill tests. All but two RCTs used a treadmill test with a 10 per cent incline. These two trials used either a graded treadmill test or treadmill testing without an incline. 19, 20 . Tables 7-9 . These results are presented by anatomical region: aorto-iliac, femoro-popliteal, and mixed aorto-iliac and femoro-popliteal artery disease. For clarity, it was decided not to list all details of the Qol assessments. Because the interventions and outcome assessments were very heterogeneous, the data could not be pooled. Therefore, the results of the individual trials are reported in brief in the following sections.
Study outcomes
All outcomes (MWD, ICD, ABPI) of the trials are shown in Figs 2-4 and
Aorto-iliac artery disease
The Mild to Moderate Intermittent Claudication (MIMIC trial) compared SET versus SET plus PTA for the aorto-iliac and femoro-popliteal regions separately. 21 For the aorto-iliac region the mean MWD increased in both groups at 6 months' follow-up compared with baseline, but significantly more in the group with additional PTA (P = 0.04). Clinical improvement, defined as walking 200 m without claudication, was attained significantly more often in the additional PTA group at 6, 12 and 24 months ( Fig. 2; table 7 ). Patients with additional PTA scored better on the SF-36 physical domain at 24 months.
Femoro-popliteal artery disease
Three trials included patients with femoro-popliteal arterial disease ( Fig. 3 ; Table 8 ).One trial comparing SET and PTA reported significantly better improvements in MWD, ICD and ABPI after PTA at 6 month follow-up. No data on Qol were reported in this trial. 18 The MIMIC trial found that patients with PTA in addition to SET had a significantly longer MWD after 24 months, but not at 6-and 12-month follow-up. The largest clinical improvement (defined as walking 200 m without claudication) observed in the SET alone group was 25 per cent at 12 months' follow-up; in the group with additional PTA the clinical improvement ranged from 32 per cent at 6 months to 63 per cent at 24 months, which was significantly better. The APBI was also significantly higher in the additional PTA group at 24 months. Qol assessed with the SF-36 was similar for all domains for both groups at 24 months. 21 The 
Mixed aorto-iliac and femoro-popliteal artery disease
The results for MWD, ICD and ABPI are presented in Fig. 4 and Table 7 -9. Five trials did not specify the level of arterial obstruction. One trial included patients with both iliac artery, superficial femoral artery (SFA) and combination disease. 13 This trial compared SET with PTA. SET conferred a significantly greater improvement in MWD and ICD than PTA at 6, 9, 12 and 15 months. The ABPI improved only in the PTA group in the first 3 months, and this was sustained at 6 and 9 months. 13 Two RCTs compared optimal medical treatment (OMT) versus OMT with additional PTA. 15, 16, 19, 20 In the first trial OMT consisted of daily aspirin, and advice on smoking and exercise. 15, 16 MWD was not different between groups after 6 and 24 months.
The ICD and ABPI improved in favour of the PTA group after 6 months, but at 24 months only the OMT group had improved further. In the second trial OMT consisted of medication, and advice on smoking, nutrition and exercise. 19, 20 The MWD and ICD were significantly increased at 3, 12 and 24 months compared with baseline. Only in the group with OMT and additional PTA did the ABPI improve significantly compared with baseline at all time points.
All improvements were significantly better in the OMT plus PTA group compared with OMT alone at the different follow-up intervals. In another RCT, patients were allocated to SET or PTA for both iliac and femoral lesions. 22, 23 Approximately 70 per cent of the patients had iliac artery disease. After 6 and 12 months of follow-up MWD, ICD and ABPI were improved compared with baseline in both groups, without significant differences between them, except for ICD at 6 months in favour of SET. The last trial compared PTA versus PTA plus SET in a majority of patients with iliac artery lesions (85 per cent). 25 The MWD increased in both Table 7 . Results for MWD, ICD and ABI in patients with aorto-iliac artery disease groups at 3 and 6 months compared with baseline, but significantly more in the PTA group.
The ABPI at 6 months was similarly improved in both groups compared with baseline. In summary, for mixed iliac and femoro-popliteal artery disease, PTA plus SET compared with PTA alone demonstrated an improvement in MWD 25 . The two trials evaluating SET versus PTA had inconsistent results: one showed a benefit in terms of MWD and ICD after SET and in ABPI after PTA13; the other trial demonstrated equal benefit in both groups, without significant differences 22, 23 . Results on MWD, ICD, ABPI and Qol from the two trials comparing OMT plus PTA versus OMT were ambivalent. 15, 16, 19, 20 For some outcomes both trials showed results in favour of OMT plus PTA. In all these trials, however, PTA was performed additionally in patients undergoing OMT (advice on smoking, nutrition and exercise plus medical therapy). Data on Qol in these five trials were assessed by seven different instruments with equivocal results.
DISCUSSION
The aim of this systematic review was to obtain the best available evidence on the relative effectiveness of PTA, (S)ET or their combination to provide recommendations for treatment of patients with IC. Owing to the heterogeneity of the interventions, especially of ET, and the assessment of outcomes, it was not possible to draw definitive conclusions. Comparing SET alone with PTA alone did not demonstrate the superiority of one treatment over the other. 13, 18, [22] [23] [24] It seems that patients benefit most from the combination of PTA and SET, although this was not observed for all outcomes. 21, 24, 25 It might be that PTA gives patients a head start for effective SET, reflected by a better increase in walking distance; however, this did not improve Qol more than SET or PTA alone. The evidence base for treatment of IC with either SET or PTA is not solid. The interpretation of the present findings is limited not only by the heterogeneity of interventions, and the heterogeneity of assessment and reporting of outcome measures, but also by shortcomings in design of individual studies.
Studies were generally of mediocre methodological quality, of small sample size and underpowered, or even conducted without a power calculation. In addition, some trials were terminated prematurely. The patients were heterogeneous with regard to baseline walking distance and mixed location of arterial lesions. Although most included studies showed that ET can improve walking distance, the most effective exercise regimen (intensity, frequency, duration) remains unknown. This was reflected in the variation in exercise programmes in the trials. Furthermore, co-interventions such as secondary prevention with antiplatelet agents or statins, which might influence the study outcomes, were different within and among trials. 
